(RTTNews) - Pfizer Inc. (PFE) on Friday said the U.S. Food and Drug Administration (FDA) has granted Priority Review to the company's supplemental Biologics License Application (sBLA) for HYMPAVZI.

Pfizer (PFE) announced on Friday that the U.S. Food and Drug Administration granted priority review for a marketing application seeking a label expansion for its hemophilia therapy, Hympavzi. The New ...

Priovant Therapeutics, a company backed by Pfizer (PFE) and Roivant Sciences (ROIV), announced on Tuesday that the U.S. FDA has granted priority review for its marketing application targeted at its ...

Pfizer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its Hympavzi hemophilia drug for two patient populations with significant medical need ...